Medical Oncology Unit, Ospedale San Paolo, Savona, Italy; Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy.
Medical Oncology Department 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Milan, Italy.
Crit Rev Oncol Hematol. 2022 Nov;179:103806. doi: 10.1016/j.critrevonc.2022.103806. Epub 2022 Sep 8.
Peripheral blood inflammatory indices, like the neutrophil-to-lymphocyte ratio (NLR), may reflect the host's pro-inflammatory status and systemic immune response to cancer-related inflammation. We reviewed 22 combined prognostic scores based on peripheral blood-derived inflammatory indices for aNSCLC patients treated with single-agent or combination immune-checkpoint inhibitors (ICI) as first-line or subsequent therapy lines and attempted evidence strength assessment and scoring. The Lung Immune Prognostic Index (LIPI), consisting of derived NLR and LDH, was the most studied score with validated prognostic value in over five thousand aNSCLC ICI-naïve or pretreated patients. The combination of NLR and tumour programmed-cell-death-ligand1 (PD-L1) expression showed a predictive value. The Lung-Immune-Prognostic score (LIPS) might help identify patients with poor performance status but a favourable outcome following first-line ICI. These non-expensive scores can help clinicians discuss the prognosis with aNSCLC patients approaching ICI, identify those less likely to benefit from single-agent ICI and orient future clinical research.
外周血炎症指标，如中性粒细胞与淋巴细胞比值（NLR），可能反映宿主的促炎状态和全身免疫反应对癌症相关炎症的反应。我们综述了 22 项基于外周血衍生炎症指标的 NSCLC 患者联合预后评分，这些患者接受单药或联合免疫检查点抑制剂（ICI）作为一线或二线治疗，尝试进行证据强度评估和评分。由 NLR 和 LDH 组成的 Lung Immune Prognostic Index（LIPI）是研究最多的评分，在五千多名未经 ICI 治疗或预处理的 aNSCLC 患者中具有验证的预后价值。NLR 与肿瘤程序性细胞死亡配体 1（PD-L1）表达的联合具有预测价值。Lung-Immune-Prognostic score（LIPS）可能有助于识别出体能状态较差但一线 ICI 治疗后预后良好的患者。这些非昂贵的评分可以帮助临床医生与接受 ICI 治疗的 aNSCLC 患者讨论预后，识别那些不太可能从单药 ICI 中获益的患者，并为未来的临床研究指明方向。
